Senti Biosciences (SNTI) Proxy filing summary

Executive summary

• The proxy filing details a proposed merger where a subsidiary will be acquired by Celadon Partners SPV 35 Limited, with stockholders receiving contingent value rights (CVRs) tied to future milestones for SENTI-202, and the company retaining Rett Syndrome and TIL programs.

• The merger consideration consists solely of CVRs, with up to $60 million payable if regulatory and commercial milestones are achieved within seven years; no cash is paid at closing.

• The board, following a special committee's recommendation and a fairness opinion from Lincoln International LLC, unanimously recommends approval of the merger and related proposals.

• The company will remain publicly traded post-merger, with a focus on early-stage gene therapy programs and a need for additional capital to sustain operations.

Voting matters and shareholder proposals

• Proposals include electing three Class I directors, ratifying KPMG LLP as auditor, approving the issuance of shares upon note conversion, approving the merger, authorizing a reverse stock split, and permitting adjournment if needed.

• The merger and share issuance require both majority stockholder approval and a majority of the minority vote, excluding affiliated entities.

• A voting agreement binds holders of 32.6% of shares to support the merger and share issuance.

• The reverse stock split proposal allows a ratio between 1-for-20 and 1-for-50 to maintain Nasdaq listing.

Board of directors and corporate governance

• The board is divided into three classes, with staggered three-year terms; nominees for Class I are Timothy Lu, Edward Mathers, and Frances D. Schulz.

• The board has audit, compensation, and nominating/governance committees, with a majority of independent directors.

• Corporate governance policies include a code of conduct, insider trading restrictions, and a compensation recovery policy.